There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Antares Pharma (ATRS), Radnet (RDNT) and Stereotaxis (STXS) with bullish sentiments.
Antares Pharma (ATRS)
Raymond James analyst Elliot Wilbur maintained a Buy rating on Antares Pharma today. The company’s shares closed last Monday at $2.89.
According to TipRanks.com, Wilbur has 0 stars on 0-5 stars ranking scale with an average return of -4.1% and a 40.6% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Amphastar Pharmaceuticals, and Amneal Pharmaceuticals.
Antares Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.
See today’s analyst top recommended stocks >>
Radnet (RDNT)
Raymond James analyst John Ransom maintained a Buy rating on Radnet today. The company’s shares closed last Monday at $18.51.
According to TipRanks.com, Ransom is a 5-star analyst with an average return of 10.3% and a 62.4% success rate. Ransom covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, AmerisourceBergen, and Tenet Healthcare.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Radnet.
Stereotaxis (STXS)
In a report released today, Jason Wittes from Northland Securities maintained a Buy rating on Stereotaxis, with a price target of $7.00. The company’s shares closed last Monday at $3.99.
According to TipRanks.com, Wittes is a 4-star analyst with an average return of 11.6% and a 58.8% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Alphatec Holdings, and Globus Medical.
Stereotaxis has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.